HighPoint Advisor Group LLC Acquires 975 Shares of Stryker Co. (NYSE:SYK)

HighPoint Advisor Group LLC lifted its stake in Stryker Co. (NYSE:SYK - Free Report) by 28.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 4,356 shares of the medical technology company's stock after purchasing an additional 975 shares during the period. HighPoint Advisor Group LLC's holdings in Stryker were worth $1,701,000 as of its most recent SEC filing.

A number of other large investors have also recently modified their holdings of SYK. Rockefeller Capital Management L.P. boosted its position in Stryker by 6.6% during the 3rd quarter. Rockefeller Capital Management L.P. now owns 54,564 shares of the medical technology company's stock valued at $19,712,000 after acquiring an additional 3,358 shares in the last quarter. Edgestream Partners L.P. lifted its stake in shares of Stryker by 216.1% in the 3rd quarter. Edgestream Partners L.P. now owns 3,430 shares of the medical technology company's stock valued at $1,239,000 after purchasing an additional 2,345 shares during the period. Kestra Investment Management LLC bought a new stake in shares of Stryker during the third quarter valued at approximately $346,000. Benjamin Edwards Inc. grew its stake in Stryker by 2,140.1% in the third quarter. Benjamin Edwards Inc. now owns 140,676 shares of the medical technology company's stock worth $50,833,000 after purchasing an additional 134,396 shares during the period. Finally, Beacon Investment Advisory Services Inc. raised its holdings in Stryker by 3.8% in the third quarter. Beacon Investment Advisory Services Inc. now owns 68,564 shares of the medical technology company's stock worth $24,769,000 after purchasing an additional 2,505 shares in the last quarter. Institutional investors own 77.09% of the company's stock.

Remove Ads

Analyst Ratings Changes

SYK has been the topic of a number of research reports. Argus set a $450.00 target price on shares of Stryker in a report on Monday, February 3rd. JMP Securities reissued a "market perform" rating on shares of Stryker in a research note on Tuesday, February 18th. Needham & Company LLC reaffirmed a "buy" rating and set a $442.00 target price on shares of Stryker in a research note on Friday, March 21st. Truist Financial boosted their price target on Stryker from $409.00 to $413.00 and gave the stock a "hold" rating in a research report on Thursday, January 30th. Finally, Canaccord Genuity Group raised their price objective on Stryker from $420.00 to $435.00 and gave the company a "buy" rating in a research report on Wednesday, January 29th. Five investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the stock. According to data from MarketBeat, Stryker presently has an average rating of "Moderate Buy" and an average target price of $421.90.

Insider Activity at Stryker

In other Stryker news, Director Allan C. Golston sold 2,458 shares of the company's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total value of $941,586.06. Following the completion of the sale, the director now owns 14,895 shares in the company, valued at $5,705,827.65. This represents a 14.16 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Ronda E. Stryker sold 201,392 shares of Stryker stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $392.24, for a total value of $78,993,998.08. Following the transaction, the director now directly owns 3,642,075 shares in the company, valued at approximately $1,428,567,498. The trade was a 5.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.50% of the stock is currently owned by company insiders.

Stryker Stock Performance

Stryker stock traded down $22.01 during midday trading on Friday, reaching $346.14. 3,956,734 shares of the company traded hands, compared to its average volume of 1,321,179. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32. Stryker Co. has a 12 month low of $314.93 and a 12 month high of $406.19. The firm has a market capitalization of $132.12 billion, a price-to-earnings ratio of 44.61, a price-to-earnings-growth ratio of 2.93 and a beta of 0.95. The business has a 50 day moving average of $381.69 and a two-hundred day moving average of $374.30.

Stryker (NYSE:SYK - Get Free Report) last released its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same period in the prior year, the company posted $3.46 EPS. As a group, research analysts predict that Stryker Co. will post 13.47 earnings per share for the current year.

Stryker Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be issued a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.97%. The ex-dividend date is Monday, March 31st. Stryker's payout ratio is 43.30%.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.